Allodynia
13
0
0
9
Key Insights
Highlights
Success Rate
82% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
15.4%
2 terminated out of 13 trials
81.8%
-4.7% vs benchmark
8%
1 trials in Phase 3/4
22%
2 of 9 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 9 completed trials
Clinical Trials (13)
Clinical Neuropharmacology of Pain in Spinal Cord Injury- Dextromethorphan Dose Response Clinical Trial
Clinical Neuropharmacology of Pain in Spinal Cord Injury- Dextromethorphan/Lidocaine Combination Clinical Trial
Music Therapy During Hypothermia in the NICU
GentleCath Air (Urinary Self-catheterization) - Pain in Female Patients With Neurological Vesico-sphincter Disorders
Evaluation of the Antihyperalgesic Effect of Tapentadol in Two Human Experimental Models
Comparison of Postoperative Nociception Between NOL-guided and Standard Intraoperative Analgesia Based on Fentanyl
Evaluation of the Efficacy of Somatosensory Rehabilitation of Pain by Vibrotactile Stimulation on Static Mechanical Allodynia
Pain Response to Cannabidiol in Opioid-induced Hyperalgesia, Acute Nociceptive Pain and Allodynia By Using a Model Mimicking Acute Pain in Healthy Adults
Pain Response to Cannabidiol in Induced Acute Nociceptive Pain, Allodynia and Hyperalgesia By Using a Model Mimicking Acute Pain in Healthy Adults
Can DFN-15 Terminate Migraine With Allodynia?
Fenobam on Heat/Capsaicin Induced Hyperalgesia in Healthy Volunteers
Botulinum Toxin Type A for Treating Allodynic Pain in SCI and MS
Botulinum Toxin Type A in Treatment of Cranial Allodynia in Patients With Headache